Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (early primary spermatocytes) | 0.10 |
| chemistry Open Targets | compounds already reach it: dexrazoxane, pazufloxacin, doxorubicin +21 | 1.00 |
| trials ClinicalTrials.gov | 6 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | PubMed did not answer (PubMed: HTTP 500) | 0.00 |
| pathways Reactome | 2 pathways; mostly protein handling | 0.90 |
No case: the score is under the bar. Receipt 17051
Sealed predictions
- TOP2A in dopamine neurons, braak-0.13 (p 0.733) → +0.43 (p 0.251)receipt 17058
Swarm cases
receipt 17058: TOP2A in dopamine neurons, braak
- power
- full sample +0.20 (p 0.429, n 18), 95% CI -0.30 to +0.61. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.23 (p 0.360, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.22 (p 0.374, n 18). could be the mix.
- skeptic
- leave-one-out range +0.10 to +0.34, sign flips 0; without severely affected donors +0.20 (p 0.429, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TOP2A in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts